More News

9 July 2019

Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

9 July 2019

Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology

9 July 2019

IGM Biosciences Announces $102 Million Series C Financing to Advance its IgM Antibody Platform and Pipeline

9 July 2019

ADC Therapeutics Announces Final Close of Series E Financing Expansion

9 July 2019

BioNTech Raises USD 325 Million in an Upsized Series B Financing to Further Advance Individualized Immuno-Oncology Pipeline

9 July 2019

MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology

8 July 2019

Skyhawk Therapeutics Announces Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

8 July 2019

Skyhawk Therapeutics Announces Expansion of Collaboration Agreement with Biogen

8 July 2019

Eisai enters into collaboration research agreement with University of Dundee on targeted protein degradation toward cancer drug discovery

3 July 2019

Mundipharma announces exclusive license and supply agreement with Prestige Biopharma for Tuznue® (HD201)

3 July 2019

New partnership to advance Nosopharm’s lead candidate to clinical stage and develop second drug candidate

3 July 2019

Confo Therapeutics and DyNAbind Announce Drug Discovery Collaboration to Identify Novel GPCR-Modulating Compounds

2 July 2019

Century Therapeutics launches with USD 250M financing for induced pluripotent stem cell (iPSC) allogeneic cell therapy platform

1 July 2019

PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics

1 July 2019

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

1 July 2019

PeptiDream Announces New Peptide Drug Conjugate (“PDC”) Collaboration Agreement with Novartis

27 June 2019

Seelos Therapeutics Announces Acquisition of an Exclusive Worldwide License of Gene Therapy Program to Address Parkinson’s Disease from Duke University

27 June 2019

ImmunoGen Announces Completion of Operational Review

27 June 2019

OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers

25 June 2019

Frontier Medicines Launches with $67 Million to Develop Novel Medicines that Drug the “Undruggable” Targets Driving Human Disease

25 June 2019

AbbVie to Acquire Allergan in Transformative Move for Both Companies

25 June 2019

ERYTECH Announces Immune Modulation Strategic Collaboration with SQZ Biotechnologies

25 June 2019

C4X Discovery and PhoreMost collaboration to accelerate Parkinson’s Disease drug discovery pipeline

25 June 2019

Gilead and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies

25 June 2019

Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis

21 June 2019

Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis

20 June 2019

Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases

20 June 2019

Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases

20 June 2019

Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership

19 June 2019

Denovo Biopharma Receives Global Rights to a Novel Late-Stage Drug for Alzheimer’s Disease from Orion Corporation for Development as a Personalized Medicine

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CD38-Targeted Antibody & Cell Therapy Pipeline Review

PSMA-Targeted Therapy Pipeline Review

Her3-Targeted Immunotherapy Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Report Package: “Drug the Undruggable” Technologies

EpCAM-Targeted Antibodies Pipeline Review

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CD73 Inhibitor Pipeline Review

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis